As one of the largest players in the supply chain, Valens is a premium cannabis producer and processor with exciting international growth potential. This is your opportunity to get on board with a truly diversified cannabis company poised to generate continuous, long-term return.
We’ve planted our roots
and we’re here to stay.
24-hour Change ($)
24-hour Change (%)
The world is our market.
With the ability to import and export internationally, Valens is set up for every servicing and consumer product opportunity, globally.
- Health Canada Dealer’s License (multiple)
- Health Canada ACMPR Cultivation and Processing License
- ISO 17025 Lab accredited – First in Canada for Cannabis
- Thermo Fisher Scientific “Centre of Excellence for Plant-Based Science”
- EU GMP Certification pending
Premium, proprietary extraction services, and R&D
Globally-recognized testing and analysis
State-of-the-art, single strain growing capabilities
Valens has received validation from an $80B company, Thermo Fisher Scientific. We’re also the preferred partner of Canopy Growth and other industry leaders.
We work with a number of renowned partners who share our commitment to innovation and supreme quality.
Medical Patients Registered in Canada by 2020
Canadian Medical Market Size
Potential Candian Recreational sales in 2019
European medical and recreational markets expected growth by 2028
The Bottom Line:
With the global legal marijuana market expected to reach 146.4 billion USD by 2025, Valens is in a rare position to capitalize on international opportunities.
The Valens Advantage.
- Full control and transparency from seed to final sale
- Proprietary methods for extraction
- Research and analysis grants
- International capabilities
- Diverse product range
Valens has already made significant strides. By the end of 2018, we will:
- Receive pending GMP certification
- Begin sales of recreational cannabis products and services to Canadian LP’s
- Commence medical sales to international markets
- Launch the Valens brand
VALENS RECEIVES ACMPR LICENSE FROM HEALTH CANADA
Kelowna, B.C., October 15th, 2018 – Valens GroWorks Corp. (CSE: VGW) (the “Company” or “Valens”), a multi-licensed, vertically integrated provider of cannabis products and services utilizing proprietary extraction processes is pleased to announce that Health Canada has granted the Company their license to cultivate and produce oil under the Access to Cannabis for Medical Purposes…
VALENS GROWORKS ANNOUNCES CLOSING OF $27.3 MILLION BOUGHT DEAL FINANCING
Kelowna, B.C., October 10, 2018 – Valens GroWorks Corp. (CSE: VGW) (the “Company” or “Valens”), a multi-licensed, vertically integrated provider of cannabis products and services utilizing proprietary extraction processes, is pleased to announce that it has closed its previously announced bought-deal prospectus offering (the “Offering”). The syndicate for the Offering was led by AltaCorp Capital…
VALENS ANNOUNCES ANNUAL AND SPECIAL MEETING RESULTS
Kelowna, B.C., October 5th, 2018 – Valens GroWorks Corp. (CSE: VGW) (the “Company” or “Valens”), a multi-licensed, vertically integrated provider of cannabis products and services utilizing proprietary extraction processes, is pleased to announce the voting results from the Company’s Annual and Special Meeting of Shareholders (“the Meeting”), held in Kelowna, British Columbia on October 5,…